SURGERY AS FEASIBLE AND SAFE MEASURE AND THERAPEUTIC MODE IN PANCREATIC METASTASES FROM RENAL CELL CARCINOMA - REAL-WORLD DATA OBTAINED IN A SINGLE HIGH-VOLUME AND CERTIFIED PANCREAS-SURGERY CENTER IN GERMANY f.meyer@med.ovgu.de

PE085

SURGERY AS FEASIBLE AND SAFE MEASURE AND THERAPEUTIC MODE IN PANCREATIC METASTASES FROM RENAL CELL CARCINOMA - REAL-WORLD DATA OBTAINED IN A SINGLE HIGH-VOLUME AND CERTIFIED PANCREAS-SURGERY CENTER IN GERMANY

8

 

 

 

 

Germany

Poster Exhibition only

Secondary malignant tumors of the pancreas are rare, representing 2-5% of all pancreas malignancies. Aim: To review retrospectively the clinical tumor registry of the University Hospital of Magdeburg, Germany, for metastatic clear cell renal cell carcinoma (CCRCC), performing a clinical systematic single-center observational study (design).

A retrospective cohort analysis of consecutive patients who had undergone pancreatic resection for metastatic CCRC was performed in a single high-volume certified center for pancreatic surgery in Germany from 2010-2022.

All patients (n=17) included in this study had a metachronous metastasis from a CCRCC but were asymptomatic. Surgery was performed at a median time interval of 12 (range, 9-16) years after primary resection for CCRCC. Three of those patients (17.6%) presented with recurrent metastasis in a different part of the pancreas during follow-up. In a total of 17 patients, including those with recurrent disease, a surgical resection was performed: pancreaticoduodenectomy, n=6 patients (35%) and left pancreatectomy with splenectomy, n=7 patients (41%). The remaining patients underwent either spleen-preserving pancreas tail, local resection of the tumor lesion or total pancreatectomy. The postoperative mortality rate was 6%. Concerning histopathological findings, seven patients (41%) had multifocal metastases. An R0-resection could be achieved in all cases. The overall survival at one, three and five years was 85%, 85% and 7%, respectively, during a median follow-up of 43 months.

CCRC pancreatic metastases can occur many years after initial treatment of primary tumor. Surgery for such a malignancy seems feasible and safe; it offers very good short- and long-term outcomes as indicated.